Last chance to save on Digiday Publishing Summit passes is February 9
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Digiday staffers tackle the creator vs. influencer divide
Creator vs. influencer: Digiday staffers debate the difference, and why it matters to marketers on this episode of the Digiday Podcast.
As ChatGPT’s growth slows, ads look like the next risky move
While launching an ad business might be good for the AI platform’s bottom line, it could cause some users to jump ship as a result.
Behind Pacsun’s strategy for keeping a pulse on the changing tastes of Gen Z
Over the last four months, Pacsun has developed tools and tweaked campaigns based on feedback from teenagers and twenty-somethings.